Bio­mea Fu­sion stock soars on ear­ly-stage di­a­betes da­ta

Red­wood City, CA-based Bio­mea Fu­sion saw about a 50% in­crease in its stock to­day af­ter re­veal­ing ear­ly da­ta for its co­va­lent menin in­hibitor, BMF-219, for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.